Urogen Pharma Ltd (URGN) financials
Urogen Pharma revenue and earnings by year
Urogen Pharma's revenue was $110 million in the fiscal year to December 31, 2025, up 21.4% from the year before. Net income was -$153 million, -139.8% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 22.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 110 | 90 | 83 | 64 | 48 | 12 | 0 | 1 | 8 | 18 |
| Revenue growth | 21.4% | 9.3% | 28.5% | 34.0% | 307.2% | 65450.0% | -98.4% | -86.2% | -53.5% | — |
| Gross profit | 97 | 82 | 73 | 57 | 43 | 11 | — | -1 | 8 | 18 |
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% | — | -59.8% | 92.6% | 99.8% |
| Operating income | -125 | -97 | -66 | -79 | -92 | -127 | -109 | -77 | -20 | 1 |
| Operating margin | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1074.2% | -608211.1% | -6842.2% | -244.5% | 4.6% |
| Net income | -153 | -127 | -102 | -110 | -111 | -128 | -105 | -76 | -20 | -2 |
| Net margin | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% | -1088.9% | -584144.4% | -6707.2% | -245.2% | -11.1% |
| Diluted EPS | -$3.19 | -$3.00 | -$3.73 | -$4.81 | -$4.96 | -$5.90 | -$5.12 | -$4.80 | -$2.06 | — |
| Free cash flow | -163 | -97 | -77 | -88 | -86 | -107 | -71 | -38 | -10 | 3 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open URGN in Markets.
How Urogen Pharma makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Zusduri | $50.4M | 69.6% |
| Jelmyto | $22.0M | 30.4% |
See also: URGN returns
No forecast, no recommendation. This page describes Urogen Pharma Ltd from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.